Irritable Bowel Syndrome Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, MOA, ROA by DelveInsight | P4 Microbiome, Biomica, Invea Therapeutics, RaQualia Pharma, RedHill Biopharma

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Irritable Bowel Syndrome pipeline constitutes 24+ key companies continuously working towards developing 24+ Irritable Bowel Syndrome treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Irritable Bowel Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Irritable Bowel Syndrome Pipeline Insight, 2024 [https://www.delveinsight.com/report-store/irritable-bowel-syndrome-ibs-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Irritable Bowel Syndrome Market.

Some of the key takeaways from the Irritable Bowel Syndrome Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Irritable Bowel Syndrome treatment therapies with a considerable amount of success over the years.

*
Irritable Bowel Syndrome companies working in the treatment market are P4 Microbiome, Biomica, Invea Therapeutics, Inc., RaQualia Pharma, RedHill Biopharma Ltd., 4D pharma, SV-MMX Cosmo Pharmaceuticals, and others, are developing therapies for the Irritable Bowel Syndrome treatment

*
Emerging Irritable Bowel Syndrome therapies such as - P4M01, BMC426, INVA 8002, RQ-00310941, RHB-102, Blautix, Rifamycin, and others are expected to have a significant impact on the Irritable Bowel Syndrome market in the coming years.

*
In February 2024, CinPhloro Pharma, a portfolio company of CinRx, has announced the dosing of the first participant in its Phase 2 enviva study evaluating CIN-103 for the chronic treatment of irritable bowel syndrome with predominant diarrhea (IBS-D). CIN-103 is a novel formulation of phloroglucinol, designed for long-term use, and is a non-opioid small molecule aimed at addressing multiple aspects of IBS-D, including motility, secretion, pain, spasms, and inflammation.

Irritable Bowel Syndrome Overview

Irritable Bowel Syndrome is a chronic, often debilitating, functional gastrointestinal (GI) disorder. It can begin in childhood, adolescence, or adulthood and can resolve unexpectedly for periods throughout an individual's lifespan, recurring at any age. The condition causes recurrent attacks of abdominal pain or discomfort in association with bowel habits. The most important single risk factors are female sex, younger age and preceding gastrointestinal infections.

Get a Free Sample PDF Report to know more about Irritable Bowel Syndrome Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/irritable-bowel-syndrome-ibs-pipeline-insight [https://www.delveinsight.com/sample-request/irritable-bowel-syndrome-ibs-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Irritable Bowel Syndrome Drugs Under Different Phases of Clinical Development Include:

*
P4M01: P4Microbiome

*
BMC426: Biomica

*
ORP-101: OrphoMed

*
INVA 8002: Invea Therapeutics, Inc.

*
RQ-00310941: RaQualia Pharma

*
RHB-102: RedHill Biopharma Ltd.

*
Blautix: 4D pharma

*
Rifamycin: SV-MMX Cosmo Pharmaceuticals

Route of Administration

Irritable Bowel Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Parenteral

*
Intravenous

*
Subcutaneous

*
Topical

Molecule Type

Products have been categorized under various Molecule types, such as

*
Monoclonal Antibody

*
Peptides

*
Polymer

*
Small molecule

*
Gene therapy

Irritable Bowel Syndrome Pipeline Therapeutics Assessment

*
Irritable Bowel Syndrome Assessment by Product Type

*
Irritable Bowel Syndrome By Stage and Product Type

*
Irritable Bowel Syndrome Assessment by Route of Administration

*
Irritable Bowel Syndrome By Stage and Route of Administration

*
Irritable Bowel Syndrome Assessment by Molecule Type

*
Irritable Bowel Syndrome by Stage and Molecule Type

DelveInsight's Irritable Bowel Syndrome Report covers around 24+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Irritable Bowel Syndrome product details are provided in the report. Download the Irritable Bowel Syndrome pipeline report to learn more about the emerging Irritable Bowel Syndrome therapies [https://www.delveinsight.com/sample-request/irritable-bowel-syndrome-ibs-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Irritable Bowel Syndrome Therapeutics Market include:

Key companies developing therapies for Irritable Bowel Syndrome are - Allergan, Ironwood Pharmaceuticals, Inc., Synergy Pharmaceuticals Inc., Bausch Health, Takeda Pharmaceutical Company Limited, AstraZeneca, Sebela Pharmaceuticals Inc., Synthetic Biologics, Inc., Astellas Pharma, Inc., and Ardelyx, and others.

Irritable Bowel Syndrome Pipeline Analysis:

The Irritable Bowel Syndrome pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Irritable Bowel Syndrome with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Irritable Bowel Syndrome Treatment.

*
Irritable Bowel Syndrome key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Irritable Bowel Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Irritable Bowel Syndrome market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Irritable Bowel Syndrome drugs and therapies [https://www.delveinsight.com/sample-request/irritable-bowel-syndrome-ibs-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Irritable Bowel Syndrome Pipeline Market Drivers

*
Increase in prevalence of gastrointestinal diseases and disorders such as alteration of bowel habit, surge in the level of Unhealthy lifestyle are some of the important factors that are fueling the Irritable Bowel Syndrome Market.

Irritable Bowel Syndrome Pipeline Market Barriers

*
However, complex diagnostic processes, lack of awareness and other factors are creating obstacles in the Irritable Bowel Syndrome Market growth.

Scope of Irritable Bowel Syndrome Pipeline Drug Insight

*
Coverage: Global

*
Key Irritable Bowel Syndrome Companies: P4Microbiome, Biomica, Invea Therapeutics, Inc., RaQualia Pharma, RedHill Biopharma Ltd., 4D pharma, SV-MMX Cosmo Pharmaceuticals, and others

*
Key Irritable Bowel Syndrome Therapies: P4M01, BMC426, INVA 8002, RQ-00310941, RHB-102, Blautix, Rifamycin, and others

*
Irritable Bowel Syndrome Therapeutic Assessment: Irritable Bowel Syndrome current marketed and Irritable Bowel Syndrome emerging therapies

*
Irritable Bowel Syndrome Market Dynamics: Irritable Bowel Syndrome market drivers and Irritable Bowel Syndrome market barriers

Request for Sample PDF Report for Irritable Bowel Syndrome Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/irritable-bowel-syndrome-ibs-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1

Irritable Bowel Syndrome Report Introduction

2

Irritable Bowel Syndrome Executive Summary

3

Irritable Bowel Syndrome Overview

4

Irritable Bowel Syndrome- Analytical Perspective In-depth Commercial Assessment

5

Irritable Bowel Syndrome Pipeline Therapeutics

6

Irritable Bowel Syndrome Late Stage Products (Phase II/III)

7

Irritable Bowel Syndrome Mid Stage Products (Phase II)

8

Irritable Bowel Syndrome Early Stage Products (Phase I)

9

Irritable Bowel Syndrome Preclinical Stage Products

10

Irritable Bowel Syndrome Therapeutics Assessment

11

Irritable Bowel Syndrome Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Irritable Bowel Syndrome Key Companies

14

Irritable Bowel Syndrome Key Products

15

Irritable Bowel Syndrome Unmet Needs

16

Irritable Bowel Syndrome Market Drivers and Barriers

17

Irritable Bowel Syndrome Future Perspectives and Conclusion

18

Irritable Bowel Syndrome Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=irritable-bowel-syndrome-pipeline-update-2024-fda-approvals-therapeutic-advancements-moa-roa-by-delveinsight-p4-microbiome-biomica-invea-therapeutics-raqualia-pharma-redhill-biopharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.